产品详情
查看大图

  • 产品名称：MouseIgG1isotypecontrol(PE-DyLight594)

  • 产品型号：
  • 产品厂商：BioLeaf
  • 产品文档：
你添加了1件商品 查看购物车
简单介绍：
MouseIgG1isotypecontrol(PE-DyLight594)
详情介绍：
Clone MOPC-21
Isotype IgG1
Specificity This mouse IgG1 kappa monoclonal antibody (clone MOPC-21) has unknown specificity and was chosen as an isotype control after screening on variety of resting, activated, live and fixed rat and human tissues.
No Cross-Reactivity Human, Rat (Rattus)
Characteristics The purified antibody is conjugated with tandem dye PE-DyLight™, 594 under optimum conditions. The reagent is free of unconjugated PE-DyLight™, 594.
Background The specificity of staining by monoclonal antibodies to target antigens should be verified by establishing the amount of non-specific antibody binding. Especially at higher concentration (more than 15 μ,g/mL) the antibody staining usually has consignable background. To this end a non-reactive immunoglobulin of the same isotype is included as a negative control for each specific monoclonal antibody used in a particular immunoassay. The monoclonal antibody MOPC-21, generated against an undefined antigen, does not react specifically with rat and human samples, and hence all the background that could be observed when working with this antibody would be a result of general nonspecific interactions between an mouse IgG1 Molecule and the respective sample under the particular conditions. This shall help the customer to set up the experimental conditions so that the nonspecific binding of any antibody is abolished.
Research Area Secondary Antibodies
Application Notes The reagent is intended as isotype control for flow cytometry analysis to establish the amount of non-specific antibody binding. For your particular experiment, use the same concentration of this isotype control antibody as the recommended working concentration of the antigen-specific antibody. Also, when working with prediluted antibodies, dilute the isotype control to the same concentration as is the concentration of the antigen-specific antibody in the prediluted antibody solution you are using. If under particular experimental conditions the background signal of the isotype control is too high (usually when working concentrations of used antibodies are above 10 µ,g per ml of incubation mixture), change the conditions of your experiment to reduce the background.
Restrictions For Research Use only
Buffer The reagent is provided in phosphate buffered saline (PBS) containing 15 mM sodium azide and 0.2 % (w/v) high-grade protease free Bovine Serum Albumin (BSA) as a stabilizing agent.
Storage 4 °C
Storage Comment Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Product cited in: Rebetz, Tian, Persson, Widegren, Salford, Englund, Gisselsson, Fan: "Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma." in: PLoS ONE, Vol. 3, Issue 4, pp. e1936, 2008 (PubMed).

Smed-Sörensen, Moll, Cheng, Loré, Norlin, Perbeck, Moody, Spetz, Sandberg: "IgG regulates the CD1 expression profile and lipid antigen-presenting function in human dendritic cells via FcgammaRIIa." in: Blood, Vol. 111, Issue 10, pp. 5037-46, 2008 (PubMed).

Yates, Rovis, Mitchell, Afzali, Tsang, Garin, Lechler, Lombardi, Garden: "The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro." in: International immunology, Vol. 19, Issue 6, pp. 785-99, 2007 (PubMed).

Carlsten, Björkström, Norell, Bryceson, van Hall, Baumann, Hanson, Schedvins, Kiessling, Ljunggren, Malmberg: "DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells." in: Cancer research, Vol. 67, Issue 3, pp. 1317-25, 2007 (PubMed).

Bryceson, March, Barber, Ljunggren, Long: "Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells." in: The Journal of experimental medicine, Vol. 202, Issue 7, pp. 1001-12, 2005 (PubMed).